PT2197878T - Composições de inibidores de quinase e sua utilização para tratamento do cancro e outras doenças associadas a quinases - Google Patents

Composições de inibidores de quinase e sua utilização para tratamento do cancro e outras doenças associadas a quinases

Info

Publication number
PT2197878T
PT2197878T PT88296009T PT08829600T PT2197878T PT 2197878 T PT2197878 T PT 2197878T PT 88296009 T PT88296009 T PT 88296009T PT 08829600 T PT08829600 T PT 08829600T PT 2197878 T PT2197878 T PT 2197878T
Authority
PT
Portugal
Prior art keywords
kinases
cancer
compositions
treatment
kinase inhibitors
Prior art date
Application number
PT88296009T
Other languages
English (en)
Portuguese (pt)
Inventor
Jia Li Chiang
Rogoff Harry
Li Youzhi
Liu Ji-Feng
Li Wei
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of PT2197878T publication Critical patent/PT2197878T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
PT88296009T 2007-09-06 2008-09-05 Composições de inibidores de quinase e sua utilização para tratamento do cancro e outras doenças associadas a quinases PT2197878T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97041007P 2007-09-06 2007-09-06
US1338907P 2007-12-13 2007-12-13
US7429508P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
PT2197878T true PT2197878T (pt) 2016-11-04

Family

ID=40429714

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88296009T PT2197878T (pt) 2007-09-06 2008-09-05 Composições de inibidores de quinase e sua utilização para tratamento do cancro e outras doenças associadas a quinases

Country Status (15)

Country Link
US (5) US8299106B2 (enExample)
EP (2) EP2197878B1 (enExample)
JP (5) JP5452490B2 (enExample)
CN (1) CN101848908B (enExample)
CA (1) CA2736177A1 (enExample)
CY (1) CY1118012T1 (enExample)
DK (1) DK2197878T3 (enExample)
ES (2) ES2759347T3 (enExample)
HR (1) HRP20161114T1 (enExample)
HU (1) HUE030774T2 (enExample)
LT (1) LT2197878T (enExample)
PL (1) PL2197878T3 (enExample)
PT (1) PT2197878T (enExample)
SI (1) SI2197878T1 (enExample)
WO (1) WO2009033033A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848908B (zh) * 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
CN105721120B (zh) * 2007-12-10 2019-12-06 交互数字专利控股公司 用于触发无线电链路控制rlc重建的方法和设备
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
US9550764B2 (en) 2012-08-23 2017-01-24 The Institute Of Cancer Research: Royal Cancer Hospital Fused heterocyclic compounds and their use
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
EP2970206A1 (en) * 2013-03-13 2016-01-20 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3010903A1 (en) * 2013-06-20 2016-04-27 Boehringer Ingelheim International GmbH Olefin substituted oxindoles having ampk activity
US9795595B2 (en) * 2014-01-27 2017-10-24 Boston Biomedical, Inc. Methods for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
MX2017013816A (es) * 2015-04-27 2018-11-12 Boston Biomedical Inc Métodos para tratar el cáncer con un inhibidor de la vía de stat3 e inhibidor de cinasas.
JPWO2017026119A1 (ja) * 2015-08-10 2018-05-24 大日本住友製薬株式会社 ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US12318381B2 (en) * 2018-09-18 2025-06-03 1Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
JP7589949B2 (ja) 2018-09-18 2024-11-26 １グローブ バイオメディカル カンパニー， リミテッド 肥満に対する処置
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132006T2 (de) * 1990-11-30 2000-08-03 Otsuka Pharmaceutical Co., Ltd. Thiazolederivate als inhibitoren von aktivem sauerstoff
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999015524A1 (en) * 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
JP2003525296A (ja) * 2000-02-28 2003-08-26 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−（ピロリルラクトン）−２−インドリノン化合物
CA2410509A1 (en) * 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
AU2004284084A1 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
JP5256047B2 (ja) * 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤
ES2369315T3 (es) * 2007-06-01 2011-11-29 F. Hoffmann-La Roche Ag Derivados de piperidina-amida.
CN101848908B (zh) * 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof

Also Published As

Publication number Publication date
PL2197878T3 (pl) 2017-01-31
US20100285006A1 (en) 2010-11-11
CY1118012T1 (el) 2017-05-17
CN101848908B (zh) 2014-07-02
JP2010538091A (ja) 2010-12-09
EP2197878B1 (en) 2016-08-17
EP2197878A2 (en) 2010-06-23
JP2015129152A (ja) 2015-07-16
EP3037419A1 (en) 2016-06-29
JP5974124B2 (ja) 2016-08-23
SI2197878T1 (sl) 2016-10-28
WO2009033033A2 (en) 2009-03-12
US20150197517A1 (en) 2015-07-16
LT2197878T (lt) 2016-09-26
CA2736177A1 (en) 2009-03-12
US9725444B2 (en) 2017-08-08
CN101848908A (zh) 2010-09-29
DK2197878T3 (en) 2016-11-14
JP2019070051A (ja) 2019-05-09
US20180022743A1 (en) 2018-01-25
US20120321622A1 (en) 2012-12-20
HK1148529A1 (en) 2011-09-09
EP3037419B1 (en) 2019-09-04
JP5701372B2 (ja) 2015-04-15
WO2009033033A3 (en) 2009-04-30
EP2197878A4 (en) 2012-02-08
ES2591028T3 (es) 2016-11-24
US8299106B2 (en) 2012-10-30
ES2759347T3 (es) 2020-05-08
US20190248781A1 (en) 2019-08-15
JP6495868B2 (ja) 2019-04-03
HK1226071A1 (en) 2017-09-22
JP2014058573A (ja) 2014-04-03
JP2016180013A (ja) 2016-10-13
JP5452490B2 (ja) 2014-03-26
HUE030774T2 (hu) 2017-05-29
HRP20161114T1 (hr) 2016-11-04

Similar Documents

Publication Publication Date Title
HUE030774T2 (hu) Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére
IL207609A0 (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
IL221556A (en) Kinase inhibitors and their use in cancer drug preparation
IL214626A0 (en) Prodrug forms of kinase inhibitors and their use in therapy
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL210494A (en) Organic compounds such as smo inhibitors, pharmaceutical preparations containing them and their use in the treatment of cancer
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
EP2696683A4 (en) COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER
IL207865A0 (en) Pim kinase inhibitors and methods of their use
PL2349260T3 (pl) Inhibitory kinazy Janus do leczenia zespołu suchego oka i innych chorób związanych z okiem
HRP20130688T1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
PL2171090T3 (pl) Markery ekspresji genów odporności guza na leczenie hamujące HER2
PT2073811E (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
ZA201202552B (en) Inhibitors of bruton's tyrosine kinase
IL214351A0 (en) Inhibitors of bruton's tyrosine kinase
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
ZA200807667B (en) Use of inhibitors of Jun N-terminal kinases to treat glaucoma
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
ZA201105917B (en) Prodrug forms of kinase inhibitors and their use in therapy
HK1166787A (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer